fda compounding semaglutide enforcement news november 2025 is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger to protect patients from unverified Beyond the Headlines: FDA Warning

Description

Do not inject into areas that are bruised, red, irritated, scarred, or have hard lumps beneath them

Potential Applications (Research Only)

They reduce appetite, improve glycaemic control and facilitate substantial weight loss

For researchers currently building protocols based on Phase 2 data, the Phase 3 dose selection validates the 4mg to 12mg range as the therapeutic window

Comparison: Clinical trials suggest that while the injection might show a slightly faster initial drop in some patients due to direct absorption, the long-term results (at 68 weeks) are comparable